
The pancreatic islet is a small endocrine unit composed of several specialized cell types working in concert to maintain glucose homeostasis, among them the insulin-producing β cell. Loss or dysfunction of β cells is central to the development of diabetes, a disease affecting hundreds of millions of people worldwide. Yet not all β cells are equal: emerging evidence shows that β cells form a heterogeneous population, with some subsets more susceptible to metabolic and immune stress than others, while some persist even under significant disease pressure. Understanding what distinguishes these surviving, resilient cells from those that are lost is central to understanding diabetes progression, and to designing better therapies.
Our lab studies this heterogeneity in the broader context of the islet microenvironment, where β cell fate is shaped not only by intrinsic cellular programs but by continuous crosstalk with resident immune cells and neighboring endocrine cells. Using transcriptomic profiling, high-resolution imaging, and CRISPR-engineered cell models across mouse and human islets, we have identified a CD24-positive β cell subset marked by distinct immune-interaction signatures. This subset is differentially represented in type 1 and type 2 diabetes, suggesting that CD24-based microenvironmental signals help determine which β cells survive, adapt, or succumb during disease.
We are particularly interested in how surface molecules on β cells mediate direct communication with islet-resident immune cells, shaping both local immune tolerance and β cell metabolic state. Our work aims to define new points of intervention to protect β cell mass and function in diabetes.